Real‑time stock data, professional analysis, and smart portfolio tools. One platform for all your investing needs.

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis – Slideshow

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis – Slideshow#Spyre #Therapeutics #SYRE #Discusses #SPY001 #Part #Induction #Topline #Results #SKYLINE #Trial #ModeratetoSevere #Ulcerative #Colitis #Slideshow

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis – Slideshow

相关文章

Wall Street bankers’ bonuses leapfrog City in ‘less impressive’ year

Fortive: Starting To Improve Its Performance

Starmer’s mentor lambasts plan to scrap juries